乌鸦传媒

In this exclusive 乌鸦传媒 video, Elizabeth Lee, MD, from the Dana-Farber Cancer Institute in Boston, offers some thoughts on how she believes endometrial cancer treatment will evolve in 2024.

Following is a transcript of her remarks:

I think there has been so much excitement about the endometrial cancer trials, as appropriate. I think there's going to be continued discussion, continued evolution specifically for our mismatch repair-proficient patients. I hope as we have more correlative data or translational studies, more histologic and molecular subject data, that that discussion will continue to evolve.

But the antibody-drug conjugates [ADCs] -- there are so many coming online now, there are so many trials that will likely have these preliminary results reading out over the next year into 2024.

And I also think an interesting thought is these combinations of ADCs -- for example, ADCs with IO [immunotherapy], ADCs with PARP [inhibitors], ADCs with other TKIs [tyrosine kinase inhibitors] -- and whether we can start to combine ADCs with other standard-of-care chemotherapies, for example with carboplatin. And potentially using our antimitotic ADC payloads to almost potentially supplant Taxol [paclitaxel], whether there's any improved efficacy or if there's potentially only just more toxicity.

I think all of these will be very interesting over the next year.

Comment